NV-001 in the Treatment of Advanced Solid Tumors

Malignant Neoplasm Clinical Trial

Official title:

A Phase I Study to Explore the Safety and Efficacy of NV-001 in the Treatment of Advanced Solid Tumors

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06051760
• Other study ID #: NV-001
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: December 1, 2023
• Est. completion date: December 1, 2024

Study information

• Verified date: September 2023
• Source: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• Contact: Dr. Wang
• Phone: 86(010)87788495
• Email: snowflake201[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a single-center, open, dose-escalation Phase I clinical study. It is designed to evaluate the safety, tolerability, preliminary efficacy and immunogenicity of treating NV-001, a king of hybrid-membrane-based tumor vaccine in patients with advanced solid tumors.

Description:

This study is a single-center, open, dose-escalation Phase I clinical study. It is designed to evaluate the safety, tolerability, preliminary efficacy and immunogenicity of treating NV-001, a king of hybrid-membrane-based tumor vaccine in patients with advanced solid tumors. The patients will be treated with vaccines generated based on their tumor tissues.Various doses will be tested according to the protocol to get preliminary safety and efficacy evidence.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 20
• Est. completion date: December 1, 2024
• Est. primary completion date: August 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• patients with histopathologically and/or cytologically confirmed non-surgically resectable advanced/metastatic solid tumors.

• patients with progression on prior standard treatment regimens or intolerance to standard treatment or no standard treatment.

• an Eastern Cooperative Oncology Group (ECOG) Physical Status (PS) score of 0 or 1 and an expected survival time of =12 weeks

• confirmed clinical or imaging progression after the most recent antitumor therapy: at least 1 measurable lesion according to RECIST 1.1 criteria.

• Substantially normal major organ function and screening laboratory values that meet the following criteria:

A. Bone marrow function: absolute neutrophil count = 1000/µL; hemoglobin = 9g/dL; platelet count = 75,000/µL.

B. Liver function: serum total bilirubin = 1.5 x upper limit of normal (ULN); serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) = 2.5 x ULN (patients with liver metastases should be = 5 x ULN); alkaline phosphatase < 2.5 x ULN (patients with liver and bone involvement should be = 5 x ULN).

C. Renal Function: Serum creatinine = 2.5 x ULN, or creatinine clearance = 30 mL/min, whether actually measured by urine collection or estimated using the Cockcroft-Gault formula.

D. coagulation: prothrombin time (PT), International Normalized Ratio (INR), and Partial Thromboplastin Time (PTT) = 1.5 × ULN.

• presence of biopsy lesions with acceptable clinical risk or lesions amenable to palliative surgical resection. Presence of a tumor lesion amenable to tumor tissue biopsy.

• have an expected survival of more than 12 weeks.

• the patient understands and complies with the study protocol and has signed the appropriate Informed Consent Form (ICF), which must be signed prior to the study procedure. 11. for patients of childbearing potential, the patient must be able to understand and comply with the study protocol.

• For patients of childbearing potential: Patients should agree to use effective contraception during treatment and for at least 90 days after the last dose of study treatment, including double-barrier contraception, condoms, contraceptive pills or injectables, and intrauterine devices (IUDs). Male patients should agree to avoid sperm donation.

Exclusion Criteria:

• has received other systemic antitumor therapy within 28 days or 5 half-lives prior to the first treatment. or has not recovered from the previous treatment (all three cases, whichever is longer);

• has received radiotherapy within 14 days prior to the first dose.

• has received a live or live attenuated vaccine within 30 days prior to the first dose.

• use of immunosuppressive drugs currently or within 14 days prior to the first dose.

• has had major surgery within 28 days or non-study related minor surgery within 7 days prior to the first dose.

• the patient has a history of allergic or hypersensitivity reactions to any of the components of NV-001.

• female patients who are breastfeeding or have a positive serum pregnancy test at the time of the screening visit.

• insufficient biopsy to complete the experiment

• any Grade 4 immune-related AE (irAE) on prior immunotherapy (patients with endocrine disorders receiving replacement therapy or experiencing asymptomatic elevations in serum amylase or lipase are eligible for enrollment), any irAE on prior immunotherapy that resulted in permanent discontinuation of therapy, or any Grade 3 irAE within = 6 months prior to initiation of treatment.

• prior toxicity from antineoplastic therapy that remains at NCI-CTCAE = Grade 2 (except for alopecia, vitiligo, and experimental indications of Grade 2 or higher as defined in the Inclusion Criteria); subjects with neurotoxicity = Grade 2 may be eligible for enrollment at the discretion of the Investigator; subjects with irreversible toxicity may be eligible for enrollment at the discretion of the Investigator.

• the presence of clinically significant pulmonary fibrosis or interstitial pneumonitis as determined by the investigator.

• the presence of clinically significant severe ophthalmic disease as determined by the investigator based on screening ophthalmologic examination.

• the presence of other malignant tumors within the previous 5 years, with the exception of cured basal cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the breast, and carcinoma in situ of the cervix.

prolonged use (=14 consecutive days) of immunosuppressive or other immunomodulatory drugs (e.g., corticosteroids: prednisone or equivalent) within 6 months, except that topical medications (e.g., ointments, eye drops, inhalers, or nasal sprays) are permitted, and topical medications must not exceed the dose recommended in the insert or if there are any signs of systemic exposure; or other acquired or congenital immunodeficiency diseases; or History of organ transplantation.

• the presence of clinically symptomatic central nervous system tumors or metastases.

• the presence of an active infection including tuberculosis (documented history, investigator judgment and radiology, and local laboratory testing), hepatitis B (hepatitis B surface antigen positive, HBV DNA above the lower limit of detection), hepatitis C (HCV antibody positive, HCV RNA positive), HIV (HIV antibody positive), and enrolled patients with viral load-negative HBV or HCV who have consented to Antiviral therapy and/or regular viral indicator monitoring as determined by the physician.

• documented primary immunodeficiency or organ transplantation.

• subjects with a history of active gastrointestinal bleeding, hemoptysis or hemorrhage.

• other conditions that may result in increased risk associated with the study medication, or affect compliance with the trial, which in the opinion of the investigator make participation in this trial inappropriate.

Related Conditions & MeSH terms

• Malignant Neoplasm
• Neoplasms

Intervention

Biological:
• NV-001
NV-001 is a type of tumor vaccine generated by hybridization of the tumor cell membrane and adjuvant membrane to stimulate the immune reactions against cancer cells.

Locations

Country	Name	City	State
China	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Progression-Free Survival (PFS)	Progression-Free Survival (PFS)	Up to 36 month
Primary	Number of Participants Experiencing dose-limiting toxicities (DLTs)	Number of Participants Experiencing dose-limiting toxicities (DLTs)	in the first 28 days after the first dose.
Primary	Number of Participants Experiencing Adverse Events (AEs)	Number of Participants Experiencing Adverse Events (AEs)	From signed ICF until the date of last visit or start new antitumor therapy, whichever comes first, assessed up to 36 months
Secondary	Overall Response Rate (ORR)	Overall Response Rate (ORR)	Up to 36 month
Secondary	Disease Control Rate(DCR)	Disease Control Rate(DCR)	Up to 36 month